Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA clears IND for phase I/II MARINA study of AOC-1001

Aug. 3, 2021

Lundbeck opens phase I study of Lu-AG-09222 in headache model

Aug. 2, 2021

Lundbeck studies Lu-AG-06466 in phase I for fibromyalgia

Aug. 2, 2021

Trk-A inhibitor E-2511 restores cholinergic neurons in transgenic models of Alzheimer's disease

Aug. 2, 2021

Changes in SavaDx and plasma P-tau181 confirm treatment effect of simufilam in AD

Aug. 2, 2021

FDA clears IND for phase I study of Protollin as treatment of AD

Aug. 2, 2021

Discovery of a novel calcitonin gene-related peptide receptor antagonist azepinone series

Aug. 2, 2021

Eli Lilly presents SAD and MAD data for LY-3372689 in healthy volunteers

July 30, 2021

Enrollment opens in phase IIa study of MT-3921 for acute traumatic cervical spinal cord injury

July 30, 2021

In vivo gene editing alleviates amyloid pathologies

July 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...